These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 28799305)

  • 41. Diagnostic Performance of the ICD-10 Code K76.82 for Hepatic Encephalopathy in Patients With Cirrhosis.
    Ozturk NB; Jamil LH; Tapper EB
    Am J Gastroenterol; 2024 Feb; 119(2):364-366. PubMed ID: 37830544
    [TBL] [Abstract][Full Text] [Related]  

  • 42.  Minimal hepatic encephalopathy in cirrhosis- how long to treat?
    Goyal O; Sidhu SS; Kishore H
    Ann Hepatol; 2017 Jan-Feb 2017; 16(1):115-122. PubMed ID: 28051800
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.
    Rahimi RS; Brown KA; Flamm SL; Brown RS
    Am J Med; 2021 Nov; 134(11):1330-1338. PubMed ID: 34242619
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Update on the Therapeutic Management of Hepatic Encephalopathy.
    Kornerup LS; Gluud LL; Vilstrup H; Dam G
    Curr Gastroenterol Rep; 2018 Apr; 20(5):21. PubMed ID: 29644492
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
    Flamm SL
    Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States.
    Volk ML; Burne R; Guérin A; Shi S; Joseph GJ; Heimanson Z; Ahmad M
    J Med Econ; 2021; 24(1):202-211. PubMed ID: 33464935
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lack of Access to Rifaximin Upon Hospital Discharge Is Frequent and Results in Increased Hospitalizations for Hepatic Encephalopathy.
    Stoll AM; Guido M; Pence A; Gentene AJ
    Ann Pharmacother; 2023 Feb; 57(2):133-140. PubMed ID: 35658580
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom.
    Berni E; Murphy D; Whitehouse J; Conway P; Di Maggio P; Currie CJ; Poole C
    Curr Med Res Opin; 2018 Nov; 34(11):2001-2008. PubMed ID: 29995455
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment options for hepatic encephalopathy.
    Schiano TD
    Pharmacotherapy; 2010 May; 30(5 Pt 2):16S-21S. PubMed ID: 20412036
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of Overt Hepatic Encephalopathy.
    Sussman NL
    Clin Liver Dis; 2015 Aug; 19(3):551-63. PubMed ID: 26195208
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy.
    Jesudian AB; Ahmad M; Bozkaya D; Migliaccio-Walle K
    J Manag Care Spec Pharm; 2020 Jun; 26(6):750-757. PubMed ID: 32463782
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
    Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.
    Sanyal AJ; Kowdley KV; Reau NS; Pyrsopoulos NT; Allen C; Heimanson Z; Bajaj JS
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38727685
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis.
    Cheng J; Chen Y; Cao W; Zuo G
    Medicine (Baltimore); 2021 Dec; 100(51):e28232. PubMed ID: 34941089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study.
    De Graeve J; Vanderstraeten E; Delvaeye T; De Lepeleere S; De Somer T; Van Steenkiste C
    Acta Gastroenterol Belg; 2022; 85(3):433-437. PubMed ID: 35833904
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
    Eltawil KM; Laryea M; Peltekian K; Molinari M
    World J Gastroenterol; 2012 Feb; 18(8):767-77. PubMed ID: 22371636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Prevention and treatment of hepatic encephalopathy].
    Sivolap YP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacotherapy for hepatic encephalopathy.
    Phongsamran PV; Kim JW; Cupo Abbott J; Rosenblatt A
    Drugs; 2010 Jun; 70(9):1131-48. PubMed ID: 20518580
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lactulose is highly potential in prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial.
    Wen J; Liu Q; Song J; Tong M; Peng L; Liang H
    Digestion; 2013; 87(2):132-8. PubMed ID: 23485720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.